CA-TIGO
23.1.2024 15:01:31 CET | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy storage solutions, today announced the launch of the Tigo GO EV Charger for the German market. A smart charging station for electric vehicles, GO EV Charger offers seamless integration with the Tigo EI Residential solar-plus-storage solution. Available as both a single and three-phase charger up to 22 kW, the GO EV Charger can be wall-mounted indoors or outdoors and includes RFID technology for easy user authentication. With flexible charging modes tailored to accommodate homeowner use cases, the GO EV Charger can be installed and connected to the Tigo EI Inverter in minutes and managed centrally from the Tigo EI monitoring platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123262185/en/
Available to the German market as a single and three-phase charger, the GO EV Charger offers flexible charging and easy management, tailored to accommodate each homeowner’s unique use case. (Photo: Business Wire)
“The synergy achieved by the integration of the charger with the solar-plus-storage solution marks a significant milestone in the journey towards a future of holistic residential energy systems,” said Klaus Besier, Managing Director at Germany’s Elektrobau Meffert GmbH, one of the first GO EV Charger customers. “As a PV installer, I believe it is crucial to have a comprehensive solution where the components are designed to work together seamlessly for an expeditious installation process. When you add the outstanding Tigo support team, which speaks the installer’s language, and the EI monitoring platform that empowers system owners to match solar energy production with their specific needs proactively, you have a winning combination. Tigo streamlines our ability to deliver more efficient and cohesive systems to more customers.”
With GO EV Charger, the Tigo EI Residential solution provides an efficient renewable energy ecosystem capable of generating, converting, storing, and managing solar energy from the roof down to the everyday needs of homeowners. On the web or through the Tigo EI App, Tigo provides homeowners with sophisticated management tools, and the Tigo Energy Intelligence platform serves as the central management platform for installers to monitor and manage the systems in their portfolios.
“Tigo’s journey first started with technological innovations to make solar safer and more efficient, followed by technologies that increase solar production and reduce operating costs as well as power conversion and energy storage, and the GO EV Charger is a natural next step in this evolution,” said Massimo Migliorini, Director Business Development EMEA – EI at Tigo Energy. “Homeowners have the capacity not only to generate clean and sustainable energy but to intelligently manage, store, and use it in once unimaginable ways. This milestone exemplifies Tigo’s unwavering commitment to renewable energy and giving individuals the power to actively contribute to a cleaner, greener future.”
The release of the GO EV Charger comes on the heels of an introductory webinar scheduled for February 5th. This will be followed by digital and live training events for German PV professionals, hosted with Tigo distribution partners in Germany between February and March. Additionally, the training offered by Tigo Academy – also available in German – will be enhanced by a series of technical content dedicated to the new Tigo solution for e-mobility.
For GO EV Charger ordering information and to get connected with an experienced member of the Tigo team, visit tigoenergy.com/contacts.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123262185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom